Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: Results from a randomized clinical trial

Surgical Infections

Volumn 4, Issue 1, 2003, Pages 57-70

  Li, Jim Zhiming ^a   Willke, Richard J ^a   Rittenhouse, Brian E ^a   Rybak, Michael J ^b  

^a PFIZER INC   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; METICILLIN; VANCOMYCIN;

AGE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; CLINICAL OBSERVATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GENDER; GEOGRAPHY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STATISTICAL MODEL; SURGICAL INFECTION; SURVIVAL;

EID: 0038744237     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629603764655290     Document Type: Article

References (56)

1. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44(Suppl A):19-23.
2. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-442.
3. Nichols RL. Preventing surgical site infections: A surgeon's perspective. Emerg Infect Dis 2001;7:220-224.
4. Smyth ET, Emmerson AM. Surgical site infection surveillance. J Hosp Infect 2000;45:173-184.
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S114-S132.
6. Mathai D, Jones RN, Stilwell M, et al. Pathogen occurrence by infection site among elderly patients from 92 medical centers in United States (US), Canada (CA), Latin America (LA), Europe (EU) and Asia-Pacific (AP) regions: a three year (1997-1999) report of antimicrobial resistances (R) from the SENTRY Antimicrobial Surveillance Program (Abstract). Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000;86.
7. Lewis RT. Soft tissue infections. World J Surg 1998; 22:146-151.
8. Cars O. Colonisation and infection with resistant gram-positive cocci. Epidemiology and risk factors. Drugs 1997;54(Suppl 6):4-10.
9. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29: 239-244.
10. File TM Jr. Overview of resistance in the 1990s. Chest 1999;115(3 Suppl):3S-8S.
11. Gales AC, Jones RN, Pfaller MA, et al. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group. Int J Infect Dis 2000;4:75-84.
12. Chambers HF. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10:781-791.
13. Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991;115:739-741.
14. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177.
15. Jones RN. Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest 2001;119(2 Suppl):397S-404S.
16. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-598.
17. Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001;184:1029-1034.
18. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001;286: 1201-1205.
19. Bukharie HA, Abdelhadi MS, Saeed IA, et al. Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diag Microbiol Infect Dis 2001;40:1-4.
20. Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001;33:990-996.
21. Charlebois ED, Bangsberg DR, Moss NJ, et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002;34:425-433.
22. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913-921.
23. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155.
24. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-411.
25. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999;5:9-17.
26. Welch KE, Goff DA, Fish DN, et al. A multicenter economic analysis of bacteremia caused by methicillin-resistant Staphylococcus aureus (abstract). Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999, American Society for Microbiology, 1999;742.
27. Lodise TP, McKinnon PS. The impact of methicillin resistance on outcomes in patients with Staphylococcus aureus bacteremia (Abstract). Abstracts of the IDSA 39th Annual Meeting, San Francisco, 2001;1229.
28. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for nosocomial Staphylococcus aureus bacteremia (SAB) (Abstract). Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001;488.
29. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988;109:619-624.
30. Hartstein AI, Mulligan ME, Morthland VH, et al. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992;30:670-674.
31. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-1231.
32. Fortun J, Navas E, Martinez-Beltran J, et al. Shorthort-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: Cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001;33:120-125.
33. Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130:155-157.
34. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: An oxazolidinone antimicrobial agent. Clin Ther 2001;23:356-391.
35. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996;39: 673-679.
36. Perry CM, Jarvis B. Linezolid: A review of its use in the management of serious gram-positive infections. Drugs 2001;61:525-551.
37. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-845.
38. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-3413.
39. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21:263-274.
40. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 2001; 20:488-494.
41. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-412.
42. Wilson SE. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and post-operative gram-positive infections. Surg Infect 2001; 2:25-35.
43. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490.
44. Grambsch PM, Therneau TM. Proportional hazards tests in diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
45. Akaike H. A new look at statistical model identification. IEEE Trans Autom Control 1974;19:716-723.
46. Hosmer Jr DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: Wiley, 1999.
47. Stata Statistical Software: Release 6.0. College Station, TX: Stata Corporation, 1999.
48. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-1846.
49. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995;29:561-565.
50. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-470.
51. Omidvari K, Deboisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia - Duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92: 1032-1039.
52. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-2454.
53. Carmeli Y, Mozaffari E. Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections. Pharmacotherapy 2002;22:55S-62S.
54. Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22:63S-70S.
55. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001;161:61-65.
56. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-971.